Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metastasis-directed therapy for oligorecurrent prostate cancer
2022-000066-18Phase 3Active
- Sponsor
- UZ Leuven
- Start
- Jan 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin, leuprolide, triptorelin and enzalutamide in prostate cancer (PCa) (3 arms), sponsored by UZ Leuven. Primary endpoint: Poly-metastatic free survival. Started Jan 2022; status: active.
02
Drugs
goserelinleuprolidetriptorelinenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-000066-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000066-18.